Fig. 4.

Osteoclastic phenotype at baseline: Bone resorption. PBMCs from patients with active or non-active RA or healthy controls were differentiated for 21 days with RANKL and M-CSF. 4a: Bone resorption was assessed at the end of the differentiation period by Toluidine Blue staining of the bone slices (arrows) (scale bar 200 μm). 4b: Quantification: The resorbed surface area was quantified (ImageJ), and reported graphically to the number of osteoclasts (μm²/osteoclast). All graphs are presented as Box-and-Whisker Plots [median, IQR (25–75)]. 4c: Correlation analysis: Correlation between BMD and bone resorption was presented graphically (95% confident bands of the best fit diagonal line are shown).